Literature DB >> 8834497

Control of the complement system.

M K Liszewski1, T C Farries, D M Lublin, I A Rooney, J P Atkinson.   

Abstract

The complement system has developed a remarkably simple but elegant manner of regulating itself. It has faced and successfully dealt with how to facilitate activation on a microbe while preventing the same on host tissue. It solved this problem primarily by creating a series of secreted and membrane-regulatory proteins that prevent two highly undesirable events: activation in the fluid phase (no target) and on host tissue (inappropriate target). Also, if not checked, even on an appropriate target, the system would go to exhaustion and have nothing left for the next microbe. Therefore, the complement enzymes have an intrinsic instability and the fluid-phase control proteins play a major role in limiting activation in time. The symmetry of the regulatory process between fluid phase and membrane inhibitors at the C4/C3 step of amplification and convertase formation as well as at the MAC steps are particularly striking features of the self/nonself discrimination system. The use of glycolipid anchored proteins on membranes to decay enzymes and block membrane insertion events is unlikely to be by chance. Finally, it is economical for the cofactor regulatory activity to produce derivatives of C3b that now specifically engage additional receptors. Likewise, C1-Inh leads to C1q remaining on the immune complex to interact with the C1q receptor. Thus the complement system is designed to allow rapid, efficient, unimpeded activation on an appropriate foreign target while regulatory proteins intervene to prevent three undesirable consequences of complement activation: excessive activation on a single target, fluid phase activation, and activation on self.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8834497     DOI: 10.1016/s0065-2776(08)60868-8

Source DB:  PubMed          Journal:  Adv Immunol        ISSN: 0065-2776            Impact factor:   3.543


  120 in total

1.  Dissociation of HIV-1 from follicular dendritic cells during HAART: mathematical analysis.

Authors:  W S Hlavacek; C Wofsy; A S Perelson
Journal:  Proc Natl Acad Sci U S A       Date:  1999-12-21       Impact factor: 11.205

Review 2.  Farming for spare body parts: silk purse or sow's ear.

Authors:  J P Atkinson
Journal:  Trans Am Clin Climatol Assoc       Date:  2001

Review 3.  Complement activation as a mediator of antiphospholipid antibody induced pregnancy loss and thrombosis.

Authors:  J E Salmon; G Girardi; V M Holers
Journal:  Ann Rheum Dis       Date:  2002-11       Impact factor: 19.103

4.  Complete sequence and genomic analysis of murine gammaherpesvirus 68.

Authors:  H W Virgin; P Latreille; P Wamsley; K Hallsworth; K E Weck; A J Dal Canto; S H Speck
Journal:  J Virol       Date:  1997-08       Impact factor: 5.103

5.  Complement regulatory activity of normal human intraocular fluid is mediated by MCP, DAF, and CD59.

Authors:  J H Sohn; H J Kaplan; H J Suk; P S Bora; N S Bora
Journal:  Invest Ophthalmol Vis Sci       Date:  2000-12       Impact factor: 4.799

Review 6.  Evolution of complement as an effector system in innate and adaptive immunity.

Authors:  J Oriol Sunyer; Hani Boshra; Gema Lorenzo; David Parra; Bruce Freedman; Nina Bosch
Journal:  Immunol Res       Date:  2003       Impact factor: 2.829

7.  Enhanced expression of the complement factor H mRNA in proliferating human RPE cells.

Authors:  Norbert Kociok; Antonia M Joussen
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2010-04-08       Impact factor: 3.117

Review 8.  Complement control protein factor H: the good, the bad, and the inadequate.

Authors:  Viviana P Ferreira; Michael K Pangburn; Claudio Cortés
Journal:  Mol Immunol       Date:  2010-08       Impact factor: 4.407

Review 9.  Experimental membranous nephropathy redux.

Authors:  Andrey V Cybulsky; Richard J Quigg; David J Salant
Journal:  Am J Physiol Renal Physiol       Date:  2005-10

Review 10.  The role of complement system in ocular diseases including uveitis and macular degeneration.

Authors:  Purushottam Jha; Puran S Bora; Nalini S Bora
Journal:  Mol Immunol       Date:  2007-09       Impact factor: 4.407

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.